Three Michigan-based companies—TSRL Inc., AnchorBio, and AAPharmaSyn—have announced the formation of The A2 BioPharm Collaborative, a new strategic collaboration aimed at accelerating drug development from target identification to IND-enabling studies.

TSRL, Inc. announced today that the company was awarded a Phase IIB Small Business Technology Transfer (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health (NIH).

TSRL, Inc. announced that in September the company was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institute of Health (NIH).

TSRL, Inc., a privately-held preclinical accelerator, has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institute of Health (NIH) for about $300,000 over 12 months.

TSRL, Inc. will continue to broaden its MAP portfolio with the development of a once-a-week patch of Trospium Chloride (TC) optimized for improved tolerance and patient outcomes in overactive bladder (OB) disease.

Ann Arbor, Michigan, September 5, 2021 – TSRL, Inc., announces its plans to develop a sHDL lead candidate for treatment of infection complications such as sepsis in collaboration with Anna Schwendeman, PhD, from University of Michigan. The company was awarded a Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of General Medical Sciences (NIGMS) of the National Institute of Health (NIH). TSRL and its collaborator, Dr. Anna Schwendeman, will receive an estimated $1.7M over the next two years to advance SPS-701 through preclinical development towards GLP toxicology testing.

TSRL, Inc., announces the continued development of microarray patch (MAP) of Zanamivir (Relenza®), an inhalation drug product licensed for the treatment and prevention of influenza A and B. TSRL has exclusively licensed the MAP technology for its flu patch from Queen’s University Belfast, Northern Ireland, UK.

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company and TSRL, Inc. (“TSRL”), a company focused on developing microneedle patches for the delivery of antivirals for the treatment of influenza, are pleased to announce that PharmaTher and TSRL (collectively the “Companies”) entered into a Co-Development Agreement to jointly develop a microneedle array patch with the aim to control the manufacturing and supply of microneedle patches for the Companies respective clinical and commercial drug programs.

TSRL, Inc., announces the continued preclinical development of a transdermal delivery system of zanamivir (Relenza®), a product licensed for the treatment and prevention of the flu.

TSRL, Inc., announces the continued development of a transdermal delivery system of zanamivir (Relenza®), an inhalation drug product licensed for the treatment and prevention of influenza A & B.

TSRL, Inc., a preclinical accelerator, announces the appointments of Martha Farmer, PhD, and Stephen Munk, PhD to the Board of Directors, and Gregory Amidon, PhD, current board member, as Chairman. In addition, Dawn Reyna was appointed to Chief Operating Officer in January of 2019.

ANN ARBOR, MICHIGAN, August 10th, 2017—TSRL, Inc., a privately-held preclinical accelerator, announced today that the company was awarded a Phase I Small Business Technology Transfer (STTR) grant and a Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy & Infectious Diseases (NIAID) of the National Institute of Health (NIH).

ANN ARBOR, MICHIGAN, February 17, 2017—TSRL, Inc., announced today that the company was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy & Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). TSRL will receive approximately $600,000 over the next two years for the development of a transdermal delivery system of zanamivir (GSK, Relenza®), an inhalation drug product used in the treatment of influenza A & B.

Sept. 26th, 2016, Ann Arbor, Michigan: RetroSense Therapeutics, a privately-held biotechnology company developing novel gene therapies for vision restoration, announced that Allergan plc has acquired all assets related to its lead development program in an all-cash transaction. RetroSense’s RST-001 program employs a photosensitivity gene to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration. Neither of these conditions have FDA-approved treatments to improve or restore vision.